GlassScriptPhysician profile
Geneva Johnson
NPI 1245004506
$800.49
in general payments reported to CMS, 2019-2025
13 companies · $537 in 2025
The $537 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $151 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $161.03 | 2025 | Opsumit, Uptravi |
| Lilly USA, LLC | $121.19 | 2024-2025 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $118.02 | 2025 | |
| Lucid Diagnostics INC. | $113.32 | 2023 | |
| Abbvie INC. | $72.61 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $39.88 | 2025 | |
| Pfizer INC. | $33.83 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.84 | 2025 | Caplyta |
| Amgen INC. | $26.79 | 2025 | Krystexxa |
| Novo Nordisk INC | $22.08 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $21.66 | 2025 | |
| Edwards Lifesciences Corporation | $21.04 | 2024 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $18.20 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geneva Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.